56
Participants
Start Date
June 30, 2009
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Dasatinib
Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.
Ixabepilone
Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
Pennsylvania Oncology Hematology Associates, Philadelphia
The Moses H. Cone Regional Cancer Center, Greensboro
Northwest Georgia Oncology Centers, Marietta
Central Georgia Cancer Care, Macon
University of Tennessee Cancer Institute, Memphis
The West Clinic, Memphis
North Coast Cancer Care, Sandusky
Hematology Oncology Associates of the Quad Cities, Bettendorf
Hematology Oncology Centers of the Northern Rockies, Billings
North Shore Cancer Research, Skokie
Hematology Oncology PC, Stamford
Baystate Medical Center, Springfield
Oncology Hematology Specialists, P.A., Denville
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Accelerated Community Oncology Research Network
OTHER